Thyroid Hormones Predict ICU Mortality After Cardiopulmonary bypass in Congenital Heart Disease Patients Under 3 Months Old

Di Yu (✉ 391122912@qq.com)  
Children's Hospital of Nanjing Medical University

Liang Zou  
children's hospital of nanjing medical university

Yueshuang Cun  
children's hospital of nanjing medical university

Yaping Li  
children's hospital of nanjing medical university

Qingfeng Wang  
children's hospital of nanjing medical university

Yaqin Shu  
children's hospital of nanjing medical university

Xuming Mo  
children's hospital of nanjing medical university

Research

Keywords: thyroid hormone, congenital heart disease, mortality

DOI: https://doi.org/10.21203/rs.3.rs-74879/v1

License: ☑️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
**Abstract**

**Background:** To study the effectiveness of thyroid hormones in predicting intensive care unit (ICU) mortality after cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).

**Methods:** We retrospective observational analyzed data from 133 patients under 3 months old who underwent cardiac surgery with CPB from June 2017 to November 2019. ICU mortality prediction was assessed by multivariate binary logistic regression analysis and area under the curve (AUC) analysis.

**Results:** Non-survivors were younger (17.46±17.10 days vs. 38.63±26.87 days, P=0.006), with a higher proportion of neonates (9/13 vs. 41/120, P=0.017) and a higher proportion of individuals with Risk Adjustment in Congenital Heart Surgery-1 (RACHS-1) score ≥4 (8/13 vs. 31/120, P=0.020). No significant difference was found in CPB and aortic cross-clamping (ACC) time. The levels of free triiodothyronine (FT3) (3.91±0.99 pmol/L vs. 5.11±1.55 pmol/L, P=0.007) and total triiodothyronine (TT3) (1.55±0.35 nmol/L vs. 1.90±0.57 nmol/L, P=0.032) were higher in survivors compared with non-survivors. In the ICU mortality prediction assessment, only FT3 was an independent mortality predictor and showed a good AUC (0.856 ± 0.040).

**Conclusion:** FT3 was a powerful and the only independent predictor of ICU mortality in CHD infants under 3 months old after CPB.

**Introduction**

Congenital heart disease (CHD) is the most common congenital malformation among live births, accounting for approximately one-third of birth defects. A systematic review showed that the prevalence of CHD increased from 0.6‰ in the 1930s to 9.1‰ at the end of the 20th century. Cardiopulmonary bypass (CPB) is often used for surgery in complex CHD cases. However, hemodilution, hypothermia and ultrafiltration during CPB have been identified as inducing a temporary hypothyroid state, especially in infants.

The thyroid hormones triiodothyronine (T3) and thyroxin (T4) have permissive effects on β1-adrenergic receptors, which enhance heart contractility and reduce systemic vascular resistance. Additionally, thyroid hormones increase preload and decrease afterload, leading to increase cardiac output. Several studies have shown that the hypothyroid state, which affects the metabolism of myocardial energy, is associated with poor prognosis after cardiac surgery with CPB. Correspondingly, thyroid hormone replacement therapy could provide clinical benefits in infants undergoing CPB.

A study was conducted to assess the effects of CPB on thyroid function in infants weighing less than 5 kg, and the results showed that low T3 and T4 were both predictors of high mortality. Talwar et al found that low levels of postoperative TT4 were correlated with postoperative morbidity, a prolonged
postoperative course, and prolonged MV in open heart surgery with CPB. Since the levels of thyroid hormones play a critical role in recovery from cardiac surgery and thyroid hormones decreased after CPB, the preoperative level of thyroid hormones could be a predictor of ICU mortality after CPB in CHD patients. Therefore, we conducted a retrospective study to evaluate the effect of thyroid hormones in relation to survival in patients after cardiac surgery with CPB.

**Methods**

We retrospectively reviewed the medical records of patients with CHD under 3 months old in our hospital between June 2017 and November 2019. We excluded patients who were over 90 days old at the time of surgery, patients without CPB, patients with primary thyroid gland disease, and patients with trisomy 21 syndrome. Clinical data included gender; age; weight; Risk Adjustment in Congenital Heart Surgery-1 (RACHS-1) score; type of CHD; preoperative levels of thyroid hormones [total T3 (TT3, normal range: 1.29–3.11 nmol/L), free T3 (FT3, normal range: 2.8–7.1 pmol/L), total T4 (TT4, normal range: 66-187.4 nmol/L), free T4 (FT4, normal range: 12.1–22 pmol/L), thyroid stimulating hormone (TSH, normal range: 0.2-5 µIU/ml)], which is a routine examination for patients with CHD in our clinic; CPB time; aortic cross-clamping (ACC) time; and ICU mortality.

**Statistical analysis**

The statistical analysis was performed with SPSS version 20.0 software (Chicago, IL, USA). Continuous variables are expressed as the mean ± standard deviation, while categorical variables are summarized as frequencies and percentages. Comparisons between groups were made using unpaired Student’s t-test for continuous variables and χ² or Fisher’s exact test for categorical variables. Multivariate binary logistic regression analysis was further conducted to assess the independent ICU mortality predictors. Receiver operating characteristic (ROC) curves were generated to examine the variables for predicting ICU mortality, and the area under the curve (AUC) was calculated from the ROC curve. Youden's index, which maximized the sum of the sensitivity and specificity, was used to define the optimal cut-off value. Statistical significance was defined as 𝑃< 0.05.

**Results**

Patient characteristics

This study enrolled 133 patients under 3 months old (with a mean age of 36.56 ± 26.78 days), including 50 neonates (37.6%). Among the participants, 39 patients (29.3%) had a RACHS-1 operative risk score ≥ 4. Based on the normal ranges mentioned above, 10(7.5%), 1(0.8%), 23(17.3%), 2(1.5%) and 48(36.1%) patients had low FT3, low FT4, low TT3, low TT4 and high TSH, respectively. A total of 13 patients (9.8%) died in the ICU; their causes of death were low cardiac output syndrome (8/133, 6.0%), sepsis (3/133, 2.3%), and brain injury (2/133, 1.5%). The demographic and physiological characteristics of the patients are presented in Table 1.
Table 1
Characteristics of enrolled patients with congenital heart disease

| Characteristic       | All patients (n = 133) |
|----------------------|------------------------|
| **Age (days)**       | 36.56 ± 26.78          |
| ≤28 days             | 50 (37.6%)             |
| >28 days and ≤ 90 days| 83 (62.4%)             |
| **Gender**           |                        |
| Male                 | 89 (66.9%)             |
| Female               | 44 (33.1%)             |
| **Weight (kg)**      | 3.89 ± 0.91            |
| **RACHS-1**          |                        |
| Score-1              | 4 (3.0%)               |
| Score-2              | 46 (34.6%)             |
| Score-3              | 44 (33.1%)             |
| Score-4              | 38 (28.6%)             |
| Score-5              | 1 (0.7%)               |
| Score-6              | 0 (0%)                 |
| **Type of Surgery**  |                        |
| ASD                  | 2 (1.5%)               |
| VSD                  | 12 (9.0%)              |
| VSD + ASD            | 50 (37.6%)             |
| COA/IAA              | 15 (11.3%)             |
| TAPVC                | 21 (15.8%)             |
| TGA                  | 19 (14.3%)             |
| PA-VSD               | 3 (2.2%)               |
| DORV                 | 2 (1.5%)               |

RACHS-1, Risk Adjustment in Congenital Heart Surgery-1; ASD, atrial septal defect; VSD, ventricular septal defect; COA, coarctation of aorta; IAA, interrupter aortic arch; TAPVC, total anomalous pulmonary venous connection; TGA, transposition of the great arteries; PA, pulmonary atresia; DORV, double outlet right ventricular; CPB, cardiopulmonary bypass; ACC, aortic cross-clamping; FT3, free triiodothyronine; FT4, free thyroxin; TT3, total triiodothyronine; TT4, total thyroxin; TSH, thyroid stimulating hormone.
| Characteristic               | All patients (n = 133) |
|-----------------------------|------------------------|
| Other                       | 9 (6.8%)               |
| **Operative factors**       |                        |
| CPB time (min)              | 114.23 ± 81.98         |
| ACC time (min)              | 46.03 ± 21.59          |
| **ICU mortality**           | 13 (9.8%)              |
| **Pre-operative thyroid function** |                    |
| FT3 (pmol/L)                | 4.99 ± 1.54            |
| FT4 (pmol/L)                | 21.28 ± 5.82           |
| TT3 (nmol/L)                | 1.87 ± 0.56            |
| TT4 (nmol/L)                | 120.25 ± 34.61         |
| TSH (µIU/ml)                | 5.72 ± 5.95            |

RACHS-1, Risk Adjustment in Congenital Heart Surgery-1; ASD, atrial septal defect; VSD, ventricular septal defect; COA, coarctation of aorta; IAA, interrupter aortic arch; TAPVC, total anomalous pulmonary venous connection; TGA, transposition of the great arteries; PA, pulmonary atresia; DORV, double outlet right ventricular; CPB, cardiopulmonary bypass; ACC, aortic cross-clamping; FT3, free triiodothyronine; FT4, free thyroxin; TT3, total triiodothyronine; TT4, total thyroxin; TSH, thyroid stimulating hormone.

Comparison of survivor and non-survivor groups

Compared with survivors, non-survivors were younger (17.46 ± 17.10 days vs. 38.63 ± 26.87 days, P = 0.006), were more likely to be neonates (9/13 vs. 41/120, P = 0.017), and had a higher proportion of RACHS ≥ 4 (8/13 vs. 31/120, P = 0.020). CPB and ACC time were slightly longer in the non-survivors, while no significant difference was found compared with the survivors. The levels of FT3, FT4, TT3 and TT4 were low and TSH was high in non-survivors; however, only FT3 (3.91 ± 0.99 pmol/L vs. 5.11 ± 1.55 pmol/L, P = 0.007) and TT3 (1.55 ± 0.35 nmol/L vs. 1.90 ± 0.57 nmol/L, P = 0.032) showed a significant difference between survivors and non-survivors. Interestingly, all non-survivors were male (Table 2).
Table 2
Characteristics of patients according to survivors and non-survivors

| Characteristic         | Survivors (N = 120) | Non-survivors (N = 13) | P value |
|------------------------|---------------------|------------------------|---------|
| Age (days)             | 38.63 ± 26.87       | 17.46 ± 17.10          | 0.006   |
| ≤28 days               | 41 (34.1%)          | 9 (69.2%)              | 0.017   |
| Female                 | 44 (36.7%)          | 0 (0%)                 | 0.005   |
| Weight (kg)            | 3.92 ± 0.93         | 3.61 ± 0.63            | 0.234   |
| RACHS-1 ≥ 4            | 31 (25.8%)          | 8 (61.5%)              | 0.020   |
| Pre-operative thyroid function |
| FT3 (pmol/L)           | 5.11 ± 1.55         | 3.91 ± 0.99            | 0.007   |
| FT4 (pmol/L)           | 21.52 ± 5.79        | 19.02 ± 5.85           | 0.142   |
| TT3 (nmol/L)           | 1.90 ± 0.57         | 1.55 ± 0.35            | 0.032   |
| TT4 (nmol/L)           | 122.07 ± 34.77      | 103.47 ± 29.10         | 0.066   |
| TSH (µIU/ml)           | 5.48 ± 4.94         | 7.89 ± 11.90           | 0.483   |
| Operative factors      |                     |                        |         |
| CPB time (min)         | 111.53 ± 83.87      | 139.07 ± 58.61         | 0.251   |
| ACC time (min)         | 45.01 ± 21.61       | 55.40 ± 19.73          | 0.100   |

Independent predictors of ICU mortality

Predictors with p-values less than 0.1 were enrolled in the multivariate binary logistic regression analysis to determine the independent predictors of ICU mortality, except gender. As shown in Table 3, FT3 was the only independent predictor.
Table 3
Multivariate logistic regression, odds ratio of variables for predicting ICU mortality in patients with congenital heart disease after cardiopulmonary bypass

| Variables | B    | S.E.  | Wald  | df | P value | OR    | 95% C.I. for OR |
|-----------|------|-------|-------|----|---------|-------|----------------|
|           |      |       |       |    |         |       | Lower          |
|           |      |       |       |    |         |       | Upper          |
| Age       | -0.036 | 0.016  | 3.406 | 1  | 0.065   | 0.965 | 0.929          |
|           |       |        |       |    |         |       | 1.002          |
| RASCH-1 ≥ 4 | -1.002 | 0.528  | 1.621 | 1  | 0.203   | 0.367 | 0.078          |
|           |       |        |       |    |         |       | 1.717          |
| ACC       | -0.003 | 0.016  | 0.038 | 1  | 0.846   | 0.997 | 0.966          |
|           |       |        |       |    |         |       | 1.028          |
| FT3       | -1.112 | 0.528  | 4.429 | 1  | 0.035   | 0.329 | 0.117          |
|           |       |        |       |    |         |       | 0.926          |
| TT3       | 2.227  | 1.437  | 2.400 | 1  | 0.121   | 9.268 | 0.554          |
|           |       |        |       |    |         |       | 155.017        |
| TT4       | -0.017 | 0.012  | 2.121 | 1  | 0.145   | 0.983 | 0.960          |
|           |       |        |       |    |         |       | 1.006          |
| Constant  | 2.560  | 1.693  | 2.286 | 1  | 0.131   | 12.937|               |

Abbreviations as in Tables 1.

Value of FT3 in predicting ICU mortality

ROC curves were constructed to examine the performance of FT3 as a predictor of ICU mortality (Fig. 1). The AUC was 0.856 ± 0.040, optimal cutoff value was 4.89 pmol/L, and sensitivity and specificity were 100% and 63.3%, respectively (Table 4).

Table 4
Value of FT3 in predicting ICU mortality

| Variable | AUC     | P value | Cutoff value | Sensitivity (%) | Specificity (%) |
|----------|---------|---------|--------------|-----------------|-----------------|
| FT3      | 0.856 ± 0.040 | 0.000   | 4.89         | 100             | 63.3            |

FT3, free triiodothyronine; AUC, area under the curve.

Discussion

To our best knowledge, the present study is the first clinical retrospective analysis of the predictable value of thyroid hormones in patients with CHD undergoing CPB. In our study of 133 consecutive patients, we found that FT3 may be an independent predictor of ICU mortality based on multivariate binary logistic regression and ROC curves. Previous studies have reported that low T3 was an independent predictor of ICU mortality, which is consistent with our finding. However, for CHD patients, especially children, RACHS-1 scores could predict ICU mortality, length of ICU stay and duration of MV. In our study, compared with survivors, non-survivors had a higher RACHS-1 score. However, in the additional multivariate binary logistic regression, it was not an independent mortality predictor. We suggest that RACHS-1 scores on the basis of CHD subtype should not consider the relationship of year, weight, and
levels of thyroid hormone as confounding factors. Additionally, the small sample size of children with RACHS-1 scores of 5 or 6 may be another reason for the reduced statistical power. Although the CPB and ACC time were high in non-survivors, no significant difference was found compared with survivors, which demonstrates the improvement of cardiac surgery techniques and perfusion mode of CPB in China.

We found an interesting phenomenon in our study, namely, that all the non-survivors were male. This could be related to the preference for sons over daughters, which is very common in China. Thus, when a child is diagnosed with complex CHD, based on the gender, operative risk and economic status of the parents, girls may not have the opportunity to undergo the operation, especially in rural areas. Due to this bias, we removed gender from the multivariate binary logistic regression.

Thyroid hormones have important effects on the cardiovascular system, such as increasing cardiac output and decreasing systemic vascular resistance, which are predictive of good outcomes. However, several studies have verified that cardiac surgery with CPB induces a marked depression of thyroid hormones. Researchers have found that low levels of T3 or T4 were correlated with postoperative morbidity in open heart surgery with CPB. A study was conducted to assess the effects of CPB on thyroid function in infants weighing less than 5 kg, and the results showed that low T3 and T4 were both predictors of high mortality. Since postoperative low levels of thyroid hormones could lead to a poor prognosis, a preoperative increase in thyroid hormones may improve the prognosis. A multicenter randomized controlled trial (RCT) of T3 supplementation of patients undergoing heart surgery with CPB (TRICC) showed that T3 supplementation provides clinical advantages in patients younger than 5 months, but not in older patients. Talwar et al performed an RCT study of perioperative oral T4 in patients younger than 6 months who underwent open heart surgery with CPB and found that thyroid hormone levels reduced postoperative and that T4 supplementation reduced the duration of MV and ICU and hospital stays. Therefore, the preoperative level of thyroid hormones may predict the prognosis of patients with CHD undergoing CPB. Kumar et al found that low T3 is an important marker of mortality in critically ill patients, while low T4 and TSH did not increase the predictability. In a large-scale prospective, observational study of unselected ICU patients, they found that FT3 was the most powerful and only independent predictor of ICU mortality among the thyroid hormone indicators. However, Quispe et al found that the FT3 level was not significantly different between survivors and non-survivors and was not a mortality predictor.

Our study showed that only FT3 is the independent predictor of ICU mortality with a good AUC. Thyroid hormones include T4, which represents the major form of circulating thyroid hormones (> 80%), and T3, which accounts for a small portion (< 20%) of circulating thyroid hormones and has a major biological effect on the heart. Moreover, the levels of TT3 and TT4 can be affected by the concentration of thyroxine-binding globulin (TBG) or the binding ability of TBG, which may be affected by several drugs, including furosemide and heparin. In contrast, FT3 and FT4 were not affected in these conditions. Thus, the level of FT3 may be better than other thyroid hormones as a predictor of ICU mortality, which is consistent with our findings.
Some limitations exist in our study. First, this was a retrospective study with a small sample size, which limited the statistical power. Therefore, additional cases need to be enrolled, and a prospective randomized multicenter study should be conducted. Second, patients with RACHS-1 scores of 5 or 6 are rare, which reduced the ability of RACHS-1 to predict ICU mortality in CHD children. Finally, we did not consider the relationship of thyroid hormones with albumin and dopamine, which may provide more robust evidence to assess the predominant predictor.

**Conclusion**

Thyroid hormones play an important role in the recovery of patients with CHD undergoing CPB, and FT3 level was the most powerful and only independent predictor of ICU mortality.

**Abbreviations**

ACC: Aortic Cross-Clamping, AUC: Area Under the Curve, CHD: Congenital Heart Disease, FT3: Free Triiodothyronine, FT4: Free Thyroxin, ICU: Intensive Care Unit, MV: Mechanical Ventilation, RACHS-1: Risk Adjustment in Congenital Heart Surgery-1, ROC: Receiver Operating Characteristic, TBG: Thyroxine-Binding Globulin, T3: Triiodothyronine, T4: Thyroxin, TT3: Total Triiodothyronine, TT4: Total Thyroxin, TSH: Thyroid Stimulating Hormone

**Declarations**

**Acknowledge**

None declared.

**Author contributions**

X.M.M. and Y.Q.S. designed the study. D.Y. and L.Z. wrote the manuscript. D.Y., L.Z. and Y.S.C. collected the data, and Y.P.L. and Q.F.W. analyzed the data. All authors reviewed the manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81370279, 81370277 and 81700288), the Science and Technology Development Fund Key Project of Nanjing Medical University (2016NJMUZD055), the Science and Technology Development Project of Nanjing (210723008) and the Social Development Project of Nanjing (201805001).

**Availability of data and material**

Please contact the author for data requests.

**Ethics approval and consent to participate**
Consent for publication

Not applicable

Competing interests

The authors declare that they have no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References

1. Dolk H, Loane M, Garne E. European Surveillance of Congenital Anomalies (EUROCAT) Working Group. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation. 2011;123(8):841–9.

2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241–7.

3. Holland FW, Brown PS, Weintraub BD, Clark RE. Cardiopulmonary bypass and thyroid function: a "euthyroid sick syndrome". Ann Thorac Surg. 1991;52(1):46–50.

4. Lerner RK, Gruber N, Pollak U. Congenital Heart Disease and Thyroid Dysfunction: Combination, Association, and Implication. World J Pediatr Congenit Heart Surg. 2019;10(5):604–15.

5. Dimmick S, Badawi N, Randell T. Thyroid hormone supplementation for the prevention of morbidity and mortality in infants undergoing cardiac surgery. Cochrane Database Syst Rev. 2004;3:CD004220.

6. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012;96(2):257–68.

7. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725–35.

8. Lynch BA, Brown DM, Herrington C, Braunlin E. Thyroid dysfunction after pediatric cardiac surgery. J Thorac Cardiovasc Surg. 2004;127(5):1509–11.

9. Kuwata S, Takanashi M, Hashimoto M, Iwamoto Y, Ishido H, Masutani S, Saiki H, Sugamoto K, Senzaki H. Thyroid Function in Patients With a Fontan Circulation. Am J Cardiol. 2019;123(6):979–83.

10. Talwar S, Bhoje A, Khadagawat R, Chaturvedi P, Sreenivas V, Makhija N, Sahu M, Choudhary SK, Airan B. Oral thyroxin supplementation in infants undergoing cardiac surgery: A double-blind placebo-controlled randomized clinical trial. J Thorac Cardiovasc Surg. 2018;156(3):1209–7.e3.

11. Marwali EM, Boom CE, Budiwardhana N, Fakhri D, Roebiono PS, Santoso A, Sastroasmor S, Slee A, Portman MA. Oral Triiodothyronine for Infants and Children Undergoing Cardiopulmonary Bypass. Ann Thorac Surg. 2017;104(2):688–95.
12. Marwali EM, Caesa P, Darmaputri S, Sani AA, Roebiono PS, Fakhri D, Djer MM, Munasir ZM, Batubara JRL, Satroasmooro S, Portman MA, Haas NA. Oral Triiodothyronine Supplementation Decreases Low Cardiac Output Syndrome After Pediatric Cardiac Surgery. Pediatr Cardiol. 2019;40(6):1238–46.

13. Mitchell IM, Pollock JC, Jamieson MP, Donaghey SF, Paton RD, Logan RW. The effects of cardiopulmonary bypass on thyroid function in infants weighing less than five kilograms. J Thorac Cardiovasc Surg. 1992;103(4):800–5.

14. Talwar S, Khadgawat R, Sandeep JA, Sreenivas V, Choudhary SK, Gupta N, Airan B. Cardiopulmonary bypass and serum thyroid hormone profile in pediatric patients with congenital heart disease. Congenit Heart Dis. 2012;7(5):433–40.

15. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg. 2002;123(1):110–8.

16. Wang F, Pan W, Wang H, Wang S, Pan S, Ge J. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care. 2012;16(1):R11.

17. Vasdev S, Chauhan S, Malik M, Talwar S, Velayoudham D, Kiran U. Congenital heart surgery outcome analysis: Indian experience. Asian Cardiovasc Thorac Ann. 2013;21(6):675–82.

18. Geier L, Menzel C, Germund I, Trieschmann U. RACHS-1 score as predictive factor for postoperative ventilation time in children with congenital heart disease. Cardiol Young. 2020;30(2):213–8.

19. Al-Radi OO, Harrell FE, Caldarone CA, McCrindle BW, Jacobs JP, Williams MG, Van Arsdell GS, Williams WG. Case complexity scores in congenital heart surgery: a comparative study of the Aristotle Basic Complexity score and the Risk Adjustment in Congenital Heart Surgery (RACHS-1) system. J Thorac Cardiovasc Surg. 2007;133(4):865–75.

20. Bobillo-Perez S, Sanchez-de-Toledo J, Segura S, Girona-Alarcon M, Mele M, Sole-Ribalta A, Cañizo Vazquez D, Jordan I, Cambra FJ. Risk stratification models for congenital heart surgery in children: Comparative single-center study. Congenit Heart Dis. 2019;14(6):1066–77.

21. Cavalcante CT, de Souza NMG, Pinto VC, Branco KM, Pompeu RG, Teles AC, Cavalcante RC, de Andrade GV. Analysis of Surgical Mortality for Congenital Heart Defects Using RACHS-1 Risk Score in a Brazilian Single Center. Braz J Cardiovasc Surg. 2016;31(3):219–25.

22. Mussino E, Miranda V, Ma L. Changes in sex ratio at birth among immigrant groups in Sweden. Genus. 2018;74(1):13.

23. Wang X, Nie W, Liu P. Son Preference and the Reproductive Behavior of Rural-Urban Migrant Women of Childbearing Age in China: Empirical Evidence from a Cross-Sectional Data. Int J Environ Res Public Health. 2020;17(9):3221.

24. Chowdhury D, Parnell VA, Ojamaa K, Boxer R, Cooper R, Klein I. Usefulness of triiodothyronine (T3) treatment after surgery for complex congenital heart disease in infants and children. Am J Cardiol. 1999;84(9):1107–9.

25. Zhang JQ, Yang QY, Xue FS, Zhang W, Yang GZ, Liao X, Meng FM. Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury
after cardiac surgery with cardiopulmonary bypass in children: A randomized, double-blind, placebo-controlled trial. Medicine. 2018;97(36):e12100.

26. Cantinotti M, Lorenzoni V, Storti S, Moschetti R, Murzi B, Marotta M, Crocetti M, Molinaro S, Clerico A, Portman M, Iervasi G. Thyroid and brain natriuretic Peptide response in children undergoing cardiac surgery for congenital heart disease-age-related variations and prognostic value. Circ J. 2013;77(1):188–97.

27. Cruz PM, Bello CN, Marcial ML, Auler Junior JO. Thyroid function profile in infants submitted to cardiac surgery with cardiopulmonary bypass. Rev Bras Anestesiol. 2004;54(3):325–34.

28. Bettendorf M, Schmidt KG, Tiefenbacher U, Grulich-Henn J, Heinrich UE, Schonberg DK. Transient secondary hypothyroidism in children after cardiac surgery. Pediatr Res. 1997;41(3):375–9.

29. Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S, TRICC Investigators. Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis. Circulation. 2010;122(11 Suppl):224-33.

30. Talwar S, Bhoje A, Khadagawat R, Chaturvedi P, Sreenivas V, Makhija N, Sahu M, Choudhary SK, Airan B. Oral thyroxin supplementation in infants undergoing cardiac surgery: A double-blind placebo-controlled randomized clinical trial. J Thorac Cardiovasc Surg. 2018;156(3):1209–7.e3.

31. Kumar KV, Kapoor U, Kalia R, Chandra NS, Singh P, Nangia R. Low triiodothyronine predicts mortality in critically ill patients. Indian J Endocrinol Metab. 2013;17(2):285–8.

32. Quispe E, Li XM, Yi H. Comparison and relationship of thyroid hormones, IL-6, IL-10 and albumin as mortality predictors in case-mix critically ill patients. Cytokine. 2016;81:94–100.

Figures
Figure 1

Receiver operating characteristic curves for free triiodothyronine (FT3)